Transaction #26674 · Form 4 · 0001193125-26-001181
Axsome Therapeutics, Inc. · Exercise / conversion · Common Stock
Axsome Therapeutics, Inc. · Transacted December 31, 2025 · Filed January 2, 2026
What does this filing report?
An SEC Form 4 filing for Axsome Therapeutics, Inc. records an exercise / conversion involving Common Stock on December 31, 2025. The reported quantity was 6,231. The filing date is January 2, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Axsome Therapeutics, Inc.
- Company CIK
- 0001579428
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 6,231
- Reported price
- 8.02
- Reference value
- 49,972.62
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 16,233
- Ownership description
- Not reported
- SEC acceptance time
- Jan 2, 2026, 7:02 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Saad Mark E ↗
Director
CIK 0001295913
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents an exercise of stock options prior to the 10-year expiration date of such options.
- F2
- Such transaction was pursuant to a pre-approved 10b5-1 plan.
- F3
- Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- F4
- Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09.
- F5
- Represents additional shares held indirectly by the Reporting Person prior to December 31, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.